Alife Health Receives CE Mark for AI Embryo Selection Tool
Alife Health has received CE Mark certification under the European Medical Device Regulation for its AI-based embryo selection software, Embryo Predict, announced in a press release. The approval allows the company to offer the product to fertility clinics across the European Union.
Embryo Predict uses deep learning to analyze embryo images and generate an AI score ranking embryos by their likelihood of resulting in a clinical pregnancy. The platform integrates with existing laboratory infrastructure to standardize embryo grading and reduce variation between embryologists.
With regulatory clearance in place, Alife plans to begin deploying the software to selected IVF centers in Europe. The company said this expansion builds on its U.S. operations, where its clinical decision support platform is already in use through partnerships with leading fertility networks.
We hope you enjoyed this article.
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from: Life Sciences
Subscribe to Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation
The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.
Read more